| Name | Mizagliflozin |
| Description | Mizagliflozin is an orally active, selective SGLT1 inhibitor with a Ki value of 27 nM for human SGLT1. Mizagliflozin is 303 times more selective for SGLT1 than for SGLT2. Mizagliflozin is an anti-diabetic drug that can improve postprandial blood sugar fluctuations and may have the potential to improve chronic constipation. |
| In vivo | METHODS: Mizagliflozin (GSK-1614235 free base) (0.3 mg/kg, intravenous administration) and oral administration (3 mg/kg, oral administration) were administered to rats to study its pharmacokinetics and metabolite profile.
RESULTS Mizagliflozin had different half-lives in rats (0.23 and 1.14 hours, respectively) depending on the administration route; the absolute bioavailability was only 0.02%; after oral administration, Mizagliflozin was mainly metabolized to its aglycone KP232 in the intestine. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.08 mM), Sonication is recommended.
Methanol : 250 mg/mL (442.74 mM), Sonication is recommended.
DMSO : 150 mg/mL (265.64 mM), Sonication is recommended.
|
| Keywords | Sodium-dependent glucose cotransporters | SGLT | selective | Mizagliflozin | KGA-3235 | KGA3235 | KGA 3235 | Inhibitor | inhibit | hSGLT2 | hSGLT1 | GSK-1614235 | GSK1614235 | GSK 1614235 | gastrointestinal | DSP-3235 | DSP3235 | DSP 3235 | disorder | constipation | Chronic | antidiabetic |
| Inhibitors Related | Dapagliflozin ((2S)-1,2-propanediol, hydrate) | Ertugliflozin L-pyroglutamic acid | Dapagliflozin | Sotagliflozin | Ipragliflozin | Canagliflozin hemihydrate | Tofogliflozin (hydrate) | Phlorizin | Phloretin | Sergliflozin A | Empagliflozin | Canagliflozin |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Glutamine Metabolism Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
